The prognostic value of standardized phase angle in adults with acute leukemia: A prospective study.
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Body Composition
Bone Marrow
/ pathology
Cell Membrane
/ pathology
Combined Modality Therapy
Female
Follow-Up Studies
Hematopoietic Stem Cell Transplantation
/ mortality
Humans
Leukemia, Myeloid, Acute
/ pathology
Male
Middle Aged
Prognosis
Prospective Studies
Survival Rate
body composition
leukemia
nutrition
phase angle
prognostic
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
01
10
2019
revised:
16
12
2019
accepted:
27
12
2019
pubmed:
13
2
2020
medline:
15
5
2021
entrez:
13
2
2020
Statut:
ppublish
Résumé
Standardized phase angle (SPhA) is a tool used to estimate body composition and cell membrane integrity. Standardized phase angle has been shown to predict survival in solid malignancies and hematopoietic stem cell transplant patients. We investigated the predictive value of SPhA on 60-day mortality, overall survival (OS), and length of hospital stay (LHS) for adults with acute myelogenous and lymphoblastic leukemia (AML and ALL). Consecutive patients ≥18 years with newly diagnosed acute leukemia receiving intensive chemotherapy were enrolled. Phase angle measurements were taken on day 1 of therapy for all patients and on the day of nadir marrow for AML patients. Measurements were standardized by BMI, gender, and age to calculate the SPhA. The difference between SPhA at nadir bone marrow compared to day 1 of induction was used to calculate change in SPhA. A cutoff of 25th percentile was used to dichotomize baseline SPhA. Among 100 patients, 88% were AML, 56% were female, and mean age was 59 years. Though not statistically significant, OS by Kaplan-Meier analysis was shorter for those below the 25th percentile SPhA compared to those above (median OS: 11.0 months vs 19.5 months; P = .09). Lower baseline SPhA was associated with increased incidence of 60-day mortality in univariable (odds ratio [OR] = 5.25; 1.35, 20.44; P = .02) but not multivariable analysis (OR = 3.12; 0.67, 14.48; P = .15) adjusted for age, creatinine, and cytogenetics. Increased change in SPhA was associated with worse OS (hazard ratio = 1.15; 1.00,1.33; P = .05) in multivariable analysis. Standardized phase angle is a rapid, noninvasive, and objective measure that may be used to inform risk stratification.
Identifiants
pubmed: 32049445
doi: 10.1002/cam4.2835
pmc: PMC7131844
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2403-2413Informations de copyright
© 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Nutr J. 2008 Jun 30;7:19
pubmed: 18590554
Br J Nutr. 2012 Apr;107(8):1217-20
pubmed: 22309898
Am J Clin Nutr. 2010 Sep;92(3):612-9
pubmed: 20631202
Haematologica. 2013 Feb;98(2):208-16
pubmed: 22875615
J Cancer Res Clin Oncol. 2006 Oct;132(10):665-71
pubmed: 16821071
Am J Clin Nutr. 2016 Mar;103(3):830-40
pubmed: 26864356
Cancer. 2015 Aug 1;121(15):2517-28
pubmed: 25891003
JPEN J Parenter Enteral Nutr. 2006 Jul-Aug;30(4):309-16
pubmed: 16804128
Clin Nutr. 2012 Dec;31(6):854-61
pubmed: 22698802
Blood. 2013 Aug 22;122(8):1366-75
pubmed: 23673859
Medicine (Baltimore). 2018 Jan;97(3):e9663
pubmed: 29505007
Ann Hematol. 2013 Jan;92(1):111-9
pubmed: 22968661
Curr Opin Clin Nutr Metab Care. 2017 Sep;20(5):330-339
pubmed: 28548972
Clin Nutr ESPEN. 2019 Feb;29:65-71
pubmed: 30661703
Br J Haematol. 2009 Jun;145(5):598-605
pubmed: 19344426
Blood. 2013 Apr 4;121(14):2618-26
pubmed: 23365464
Eur J Clin Nutr. 2013 Jan;67 Suppl 1:S2-9
pubmed: 23299867
Blood. 2010 Jan 21;115(3):453-74
pubmed: 19880497
Scand J Med Sci Sports. 2017 Nov;27(11):1308-1316
pubmed: 27541287
JPEN J Parenter Enteral Nutr. 2015 Sep;39(7):787-822
pubmed: 26287016
Leuk Res. 2013 Sep;37(9):998-1003
pubmed: 23747082
BMC Cancer. 2009 Jan 28;9:37
pubmed: 19175932
Clin Nutr. 2004 Dec;23(6):1430-53
pubmed: 15556267
Blood. 2008 Mar 1;111(5):2563-72
pubmed: 18156492
Support Care Cancer. 2010 Feb;19(2):187-92
pubmed: 20039074
Nutrition. 2017 Sep;41:120-125
pubmed: 28760421
BMC Cancer. 2008 Aug 27;8:249
pubmed: 18727837
Blood. 2010 Nov 25;116(22):4422-9
pubmed: 20668231
Clin Nutr. 2015 Jun;34(3):496-500
pubmed: 24953772
Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):8-13
pubmed: 25696829
Cancer. 2006 Mar 1;106(5):1090-8
pubmed: 16435386
Cancer Med. 2020 Apr;9(7):2403-2413
pubmed: 32049445
Am J Phys Anthropol. 2003 Dec;122(4):361-70
pubmed: 14614757
Blood. 2009 Jan 1;113(1):28-36
pubmed: 18827183
Nutr Clin Pract. 2019 Jun;34(3):381-386
pubmed: 29870080
J Crit Care. 2018 Apr;44:430-435
pubmed: 29353120
JPEN J Parenter Enteral Nutr. 2017 Sep;41(7):1131-1138
pubmed: 27221673
Blood. 2013 May 23;121(21):4287-94
pubmed: 23550038
Lancet. 2010 Dec 11;376(9757):2000-8
pubmed: 21131036
Blood. 2017 Jan 26;129(4):424-447
pubmed: 27895058
Hematol Oncol. 2019 Feb;37(1):80-84
pubmed: 30105853
J Clin Oncol. 2011 Jul 10;29(20):2758-65
pubmed: 21632498